

## IMMATICS PRESS RELEASE

### **Immatics Presents First Cohort Data on the ACTolog® Personalized Multi-Target Cell Therapy Trial Demonstrating Safety and T-cell Persistence in Treated Cancer Patients**

**San Francisco, July 19, 2019** - Immatics Biotechnologies GmbH, a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting cancer immunotherapies, announced today a comprehensive data set having completed the first cohort of the ACTolog® Personalized Multi-Target T-cell Therapy Trial (Study code: IMA101-101, [NCT02876510](#)) at the [AACR Special Conference on Immune Cell Therapies for Cancer](#).

ACTolog® is an adoptive cell therapy (ACT) product using the patient's own (autologous), non-genetically engineered (endogenous) T cells. "To our knowledge, this is the first time that patients are being treated with multiple defined cell therapy products directed against multiple specific tumor targets. For each of the T-cell products the actual expression of the targets is confirmed in a fresh tumor biopsy taken prior to product manufacturing. ACTolog® is taking personalized cell therapy to the next level – aiming to provide effective treatments for patients with advanced solid cancers", states Dr. Harpreet Singh, CEO of Immatics.

The ACTolog® approach has been pioneered by [Prof. Cassian Yee](#) at MD Anderson and expanded by Immatics to include multiple proprietary cancer targets discovered by Immatics' XPRESIDENT® platform. The trial is led by Principal Investigator [Prof. Apostolia M. Tsimberidou](#) and Co-Principal Investigator [Prof. Borje S. Andersson](#) with collaboration from other MD Anderson colleagues.

The data set will be provided in three oral presentations and two poster presentations by Prof. Tsimberidou, Dr. Nowak and Dr. Singh – for details see below.

The main conclusions from the currently available data set (N=9 patients, immune data for N=7 patients) are:

- All patients entered the trial with progressive disease, having failed the previous line of therapy. Median duration of disease of the patients was 4 years (range 2-18 years) with a median of 6 previous rounds of treatment (range 3-12). Patients received a median of 2 target-specific ACTolog® products (range 1-3).
- ACTolog® IMA101 is well tolerated. The most common adverse events, as expected, were cytopenias associated with the lymphodepleting regimen and Grade 1-2 cytokine release syndrome.
- High frequencies and persistence of target-specific CD8+ T cells of up to 50% of peripheral CD8+ T cells (measured *ex vivo*) were observed within the blood of patients up to 12 weeks after adoptive transfer.
- Comprehensive cellular immunomonitoring indicates a favorable phenotype of infused T cells.
- All treated patients had stable disease by RECIST and irRECIST at 6 weeks and are alive to date after a median follow-up of 8 months.

The trial is part of a series of research programs and clinical trials conducted in a [strategic alliance](#) between Immatics and MD Anderson. The ACTolog® T-cell products are manufactured at the [Evelyn H. Griffin Stem Cell Therapeutics Research Laboratory](#) in collaboration with The University of Texas Health Science Center in Houston (UTHealth).

### **About Immatics**

Immatics is a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting immunotherapies for the treatment of cancer. The Company's transformative product candidates are – best in class – [Adoptive Cell Therapies \(ACT\)](#) and [Bispecific TCR molecules](#). These products are directed against tumor targets that have been identified and validated by Immatics' proprietary and world-leading [XPRESIDENT®](#) technology. XPRESIDENT® is the most sensitive, unbiased and high-throughput technology capable of identifying targets in virtually any type of cancer and any HLA type. Together with Immatics' powerful TCR discovery technology [XCEPTOR®](#), these two platforms allow a full range of cancer therapies to be developed.

Immatics' pipeline includes T-cell therapy programs based on the proprietary ACTolog®, ACTengine® and ACTallo® approaches, which are developed in collaboration through Immatics US with the University of Texas MD Anderson Cancer Center and co-funded by the Cancer Prevention and Research Institute of Texas (CPRIT), and several bispecific TCR and antibody molecules.

Operating from Tuebingen, Munich (Germany) and Houston (Texas), the Company has recognized that novel, better and safer targets are the key to developing future cancer immunotherapies and it is Immatics' mission to deliver the power of T cells to cancer patients.

For regular updates about Immatics, visit [www.immatics.com](http://www.immatics.com). And follow us on [Twitter](#) and [LinkedIn](#).

### **About ACTolog® T-cell Therapy**

The ACTolog® concept is one of the first actively personalized, multi-targeted Adoptive Cell Therapies (ACT). It is based on the principle of endogenous T-cell therapy pioneered by Professor Cassian Yee, M.D. Unlike tumor-infiltrating lymphocytes, ACTolog® T-cell products are generated from peripheral blood cells with defined target selectivity. Utilizing its proprietary antigen discovery platform XPRESIDENT®, Immatics has created a warehouse of eight cancer targets. From this warehouse, the most suitable targets for each patient's tumor are identified by analyzing the tumor biomarkers. Up to four personalized T-cell products are then manufactured for each patient by activation and enrichment of the patient's specific endogenous T cells in vitro. Billions of such activated and specific T cells are then re-infused into the cancer patient to attack the tumor. The ACTolog® T-cell products are manufactured at the Evelyn H. Griffin Stem Cell Therapeutics Research Laboratory in collaboration with the University of Texas Health Science Center in Houston (UTHealth).

### **For more information, please contact:**

Anja Heuer  
Corporate Communications  
Immatics Biotechnologies GmbH  
Phone : +49 89 540415-606  
[media@immatics.com](mailto:media@immatics.com)

Chad Rubin  
Investor Relations  
Solebury Trout  
Phone: +1 646 378-2947  
[crubin@soleburytrout.com](mailto:crubin@soleburytrout.com)

You have received this information due to your interest in Immatics (Immatics Biotechnologies GmbH / Immatics US, Inc.). We hope you find this information useful to update you on the developments at Immatics. Immatics would like to continue to send you information by e-mail. If you would prefer not to receive these e-mails, please [unsubscribe here](#).

## Presentations at the AACR Special Conference on Immune Cell Therapies for Cancer

Saturday, July 20, 8-10am PT

Plenary Session 1: Cellular Therapy Clinical Updates I

**Cellular immunomonitoring for the first personalized adoptive cellular therapy trial using defined multiple targets (ACTolog® IMA101-101)**

Presenter: Anna Nowak, Immatics

Saturday, July 20, 12:30-2:30pm PT

Poster Session A, Abstract A14

**“Phase I adoptive cellular therapy trial with endogenous CD8+ T cells (ACTolog® IMA101) in patients with relapsed and/ or refractory solid cancers”**

Principal Investigator: Apostolia M. Tsimberidou, MD Anderson Cancer Center

Presenter: Harpreet Singh, Immatics

Sunday, July 21, 8-10am PT

Plenary Session 5: Cellular Therapy Clinical Updates II

**“Phase I adoptive cellular therapy trial with endogenous CD8+ T cells (ACTolog® IMA101) in patients with relapsed and/ or refractory solid cancers”**

Principal Investigator: Apostolia M. Tsimberidou, MD Anderson Cancer Center

Presenter: Harpreet Singh, Immatics

Sunday, July 21, 10:30am-12:15pm PT

Plenary Session 6: Optimization of Target Antigens for TCR and TIL

**“Novel naturally presented targets for personalized T-cell therapies”**

Presenter: Harpreet Singh, Immatics

Sunday, July 21, 4:30pm-6:30pm PT

Poster Session B, Abstract B15

**“Cellular immunomonitoring for the first personalized adoptive cellular therapy trial using defined multiple targets (ACTolog® IMA101-101)”**

Presenter: Anna Nowak, Immatics